Halozyme Therapeutics Inc. (HALO) 12-Month Stock Forecast & Price Target Cone
Halozyme Therapeutics Inc. (HALO) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Drag to Test Your HALO Position Size: $10,000
Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)
Street Historical Accuracy: 64/100| Wall Street Firm | Stance | 12M Target | 1Y Accuracy | Track Grade |
|---|---|---|---|---|
| Morgan StanleyInstitutional Equity Desk | HOLD | $142 | 74% | A |
| Goldman SachsSector Coverage Lead | BUY | $151 | 69% | B |
| JP MorganUS Large-Cap Research | HOLD | $121 | 58% | C |
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live HALO Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
HALO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.
HALO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is HALO's 12-month stock price target?
Halozyme Therapeutics Inc. (HALO) carries a 12-month consensus base price target of $136.49 (+4% from $131.18), with a bull-case target of $161.06 and a bear-case floor of $106.46.
Is HALO stock a Buy, Hold, or Sell right now?
Roarable's 5-Pillar RQD Quant Engine rates HALO C+ (Hold — HOLD) with an RQD Confidence score of 67/100.